GenScript has officially opened its first European mRNA production site in Delft, the Netherlands.
The Delft facility strengthens GenScript’s transatlantic biotechnology infrastructure, enabling greater regional proximity, regulatory alignment, and supply chain resilience for European innovators developing next-generation therapies, vaccines, and advanced biologics.
“Having a local GenScript facility in the EU makes a real difference for us,” said Paula RÃo, Hematopoietic Innovative Therapies Unit, CIEMAT/CIBERER/FJD, UAM.
“The closer proximity enables more seamless collaboration, faster turnaround times, and reduced shipping delays. Working with a team that’s fully aligned with EU regulations and standards strengthens the partnership and makes day‑to‑day interactions significantly easier.”
This ability to translate global capabilities into regionally embedded, customer‑ready infrastructure reflects GenScript’s broader platform strategy. As a US-founded biotechnology company, GenScript continues to expand its innovation footprint across North America and Europe through long-term investment in scalable platform infrastructure.
“Europe is not an outpost in our network; it is a core pillar of our global mRNA platform,” said Shawn Wu, president of GenScript EU Division.
“By integrating Delft into our unified global operating system, we are delivering greater speed, regulatory alignment, and operational resilience for our partners, while maintaining one uncompromising global standard.”
The Delft site provides end-to-end mRNA workflow capabilities, including: gene design and synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping technology, and UTR optimisation and formulation support.
The facility operates within GenScript’s AI-enabled digital operating model, supporting process consistency, accelerated turnaround times, and seamless integration with the company’s global R&D and manufacturing network.
The Delft opening follows GenScript’s continued expansion of its US innovation footprint, including capacity growth at its New Jersey site, and complements its broader global operations across North America, Europe, and Asia.
GenScript established its European Division headquarters in the Netherlands in 2021 and has steadily expanded regional operations since then. The Delft mRNA site strengthens local access to advanced mRNA technologies while maintaining global scale.
“From our first conversations, GenScript has demonstrated a strong commitment to innovation, collaboration, and scientific excellence,” said Cindy Gerhardt, managing director of Planet B.io.
“We’ve built a valuable partnership driven by a shared ambition to accelerate biotech research and innovation. The opening of this state-of-the-art lab strengthens the position of the Biotech Campus Delft—not only for our own community, but for the broader European biotech ecosystem.”
“This expansion reflects disciplined execution of our global platform strategy,” said Sherry Shao, CEO of GenScript Biotech Corporation.
“As a US-founded company committed to advancing biotechnology worldwide, we continue to invest in resilient, regionally anchored infrastructure that supports innovation with speed, quality, and trust. At GenScript, ‘Scripting Possibilities’ means building the integrated global systems that allow science to move confidently from discovery to development, across regions, and at scale.”